To avoid the non-specific cytokine storms, recombinant bi-specific derivatives were created lacking the Fc, such as Blinatumomab, which is a BiTE made up of two scFvs targeting CD19 and CD3, that was approved by the FDA in December 2014 and by the EMA in December 2015 for the treatment of the ALL [6, 7]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.